Artículo
Latin American Experience with Alzheimer's Disease Cerebrospinal Fluid Biomarkers
Surace, Ezequiel Ignacio
; Cohen, Gabriela; Martinetto, Horacio Enrique
; Chrem Mendez, Patricio Alexis; Martin, Eugenia; Smith, Elisa; Russo, Griselda; Amengual, Alejandra; Allegri, Ricardo Francisco
; Leiguarda, Ramón C.; Sevlever, Gustavo; Campos, Jorge
Fecha de publicación:
07/2013
Editorial:
William B. Applegate
Revista:
Journal Of The American Geriatrics Society
ISSN:
1532-5415
Idioma:
Inglés
Tipo de recurso:
Artículo publicado
Clasificación temática:
Resumen
A promising advance to complement clinical diagnosis at an early stage of Alzheimer’s disease (AD) has been the measurement of biomarkers in cerebrospinal fluid (CSF).1 A decrease in CSF amyloid beta 42 (Ab42) is a marker of AD pathology caused by the accumulation of amyloid-b in brain parenchyma,2 whereas increased total tau (t-tau) and hyperphosphorylated tau (p-tau) reflect neuronal degeneration and tangle pathology.3 AD is characterized by episodic memory loss, cognitive impairment, behavioral disorders, and finally, dementia.4 Individuals with mild cognitive impairment (MCI) have memory defi- cits but, in contrast to those with AD, are functionally intact and at higher risk of converting to AD than those without MCI.4 It is difficult to predict clinically which individuals with MCI possess AD brain pathology and will therefore progress to clinical AD
Palabras clave:
Cerebrospinal
,
Biomarkers
Archivos asociados
Licencia
Identificadores
Colecciones
Articulos(SEDE CENTRAL)
Articulos de SEDE CENTRAL
Articulos de SEDE CENTRAL
Citación
Surace, Ezequiel Ignacio; Cohen, Gabriela; Martinetto, Horacio Enrique; Chrem Mendez, Patricio Alexis; Martin, Eugenia; et al.; Latin American Experience with Alzheimer's Disease Cerebrospinal Fluid Biomarkers; William B. Applegate; Journal Of The American Geriatrics Society; 61; 7; 7-2013; 1229-1231
Compartir
Altmétricas